Rhopressa

Drug Overview

Dealing with elevated intraocular pressure requires careful management to preserve your vision over time. We understand the anxieties associated with chronic ocular conditions. Fortunately, modern medicine provides highly effective ways to manage this pressure. Netarsudil is an innovative medication in the Ophthalmology drug category. As a specialized treatment in the ROCK Inhibitor drug class, it represents a unique and advanced approach to eye care.

• Generic Name: Netarsudil
• US Brand Names: Rhopressa
• Route of Administration: Topical Drops
• FDA Approval Status: FDA-Approved for the reduction of elevated intraocular pressure.

What Is It and How Does It Work? (Mechanism of Action)

Netarsudil is a specialized targeted therapy     designed to lower intraocular pressure (IOP). High eye pressure occurs when the aqueous humor (the clear fluid inside the eye) cannot drain efficiently.

At a cellular and physiological level, netarsudil functions as a Rho kinase (ROCK) inhibitor. The trabecular meshwork is the eye’s primary drainage pathway. In patients with glaucoma, the cells in this meshwork become stiff, resisting natural fluid flow. Netarsudil works by inhibiting the Rho kinase enzyme, which causes the cells in the trabecular meshwork and the inner wall of Schlemm’s canal to physically relax. This relaxation significantly increases the trabecular outflow of aqueous humor. Furthermore, netarsudil lowers episcleral venous pressure, which further reduces the downstream resistance to fluid leaving the eye. This dual-action targeted therapy     effectively reduces intraocular pressure, protecting your delicate optic nerve from irreversible damage.

FDA-Approved Clinical Indications

• Primary Indication: Reduction of elevated intraocular pressure (IOP) in adult patients with open-angle glaucoma or ocular hypertension.
• Other Approved & Off-Label Uses:
  • Primary Ophthalmology Indications:
    • Open-angle glaucoma: Used to actively lower and manage eye pressure to prevent the progressive loss of visual acuity and peripheral vision.
    • Ocular hypertension: Used proactively to manage intraocular pressure before structural vision loss or optic nerve damage occurs.
  • Off-label use: Investigated by specialists to promote corneal endothelial cell healing in specific chronic ocular surface diseases or dystrophies.

Dosage and Administration Protocols

Administration Instructions and Adjustments:

• Wash hands thoroughly with soap and water before use.
• Remove contact lenses before instilling the drops. Wait at least 15 minutes before reinserting your lenses, as the preservative in the medication can be absorbed by soft contact lenses.
• If you are using other topical eye medications, wait at least 5 minutes between different drops to avoid washing the previous medication out of your eye.
• Practice the technique for punctal occlusion: gently press the inner corner of your eye (near the nose) for one minute after instillation to keep the medicine in the eye and minimize systemic absorption.

Dosage must be individualized by a qualified healthcare professional.

Clinical Efficacy and Research Results

Current clinical data (2020-2026) validates netarsudil’s strong performance in eye care. Because it targets a completely unique physiological pathway compared to older glaucoma medications, it is highly efficacious in preventing vision loss.

In comprehensive Phase 3 clinical trials, patients using netarsudil 0.02% experienced a clinically significant reduction in Intraocular Pressure (IOP). For patients with baseline pressures ranging from 20 to 27 mmHg, studies demonstrated an average reduction in IOP of 3 to 5 mmHg. Long-term follow-up research confirms that it maintains this pressure reduction without losing efficacy over years of use. Optical Coherence Tomography (OCT) scans of treated patients show stabilization of the retinal nerve fiber layer, proving the drug successfully halts the mechanical damage caused by high eye pressure, thereby preserving the patient’s Best Corrected Visual Acuity (BCVA).

Safety Profile and Side Effects

Currently, there is no “Black Box Warning” associated with netarsudil. It is generally well-tolerated, though localized surface reactions are very common due to its mechanism of action.

Common Side Effects (>10%):

• Conjunctival hyperemia (eye redness): Affecting over 50% of patients, this is caused by the harmless relaxing of blood vessels on the eye’s surface.
• Corneal verticillata (whorl keratopathy): An asymptomatic, swirling deposit pattern on the cornea, usually detected only during an eye exam.
• Instillation site pain or mild stinging upon applying the drop.
• Conjunctival hemorrhage (small, broken blood vessels on the white part of the eye).

Serious Adverse Events:

• Systemic absorption leading to cardiovascular issues (like bradycardia or hypotension) is exceedingly rare with this class of medication, unlike older beta-blocker drops.
• Severe allergic reactions or corneal melting are exceptionally rare but require immediate medical attention.

Management Strategies:

To manage the common side effect of eye redness, patients are advised to use the drop in the evening so that peak redness occurs during sleep. Employing sterile administration techniques and proper drop instillation (punctal occlusion) minimizes both the risk of infection and systemic exposure. Always monitor for sudden pain, extreme light sensitivity, or sudden visual changes.

Research Areas

Robust current research focuses on netarsudil’s direct clinical connections to corneal health. Beyond simply decreasing aqueous outflow resistance, scientists are heavily studying its interaction with the corneal endothelium. The ROCK inhibitor pathway naturally promotes the health, migration, and regeneration of corneal endothelial cells, offering massive potential for patients suffering from Fuchs’ endothelial corneal dystrophy.

Active clinical trials (2020-2026) are also exploring advancements in Novel Delivery Systems, such as formulating netarsudil into sustained-release intraocular implants that could entirely eliminate the need for daily drops. Further research targets Severe Disease & Surgical Integration, specifically assessing the drug’s use as an adjunct to corneal transplants (like DMEK or DSAEK) to accelerate graft adherence and cellular recovery.

Disclaimer: These studies regarding sustained-release intraocular implants and primary use for corneal regeneration are currently in the preclinical phase and are not yet applicable to practical or professional clinical scenarios.

Patient Management and Clinical Protocols

Pre-treatment Assessment

A thorough baseline evaluation ensures patient safety and treatment viability before starting the drops.

• Baseline Diagnostics: Comprehensive assessment including Tonometry (IOP measurement at different times of the day) and detailed Slit-lamp exam findings to evaluate the ocular surface.
• Ocular Imaging: Optical Coherence Tomography (OCT) to measure retinal nerve fiber layer thickness, and Fundus Photography to document the optic nerve.
• Specialized Testing: Visual field testing (perimetry) to map any existing peripheral vision loss, and Gonioscopy to confirm open drainage angles.
• Screening: Check for a history of allergies to preservatives like benzalkonium chloride (BAK), which is used in the bottle.

Monitoring and Precautions

Ongoing clinical care ensures the medication remains safe, effective, and well-tolerated over time.

• Vigilance: Regular IOP monitoring is required. Doctors will also monitor for severe conjunctival hyperemia, which can be cosmetically bothersome to some patients.
• Lifestyle: Wear proper UV protection (sunglasses) outdoors. Practice eyelid hygiene (lid scrubs) to keep the ocular surface healthy and reduce irritation.
• “Do’s and Don’ts” list:
  • DO use the drop consistently every single evening.
  • DO keep all follow-up appointments for routine pressure checks and visual field tests.
  • DON’T stop taking the medication abruptly without speaking to your doctor, as your eye pressure will rapidly rise again.
  • DON’T let the tip of the dropper bottle touch your eye, eyelashes, or fingers to maintain strict sterility.

Legal Disclaimer

The information provided in this guide is for educational and informational purposes only and does not constitute medical advice. It is not intended to be a substitute for professional medical diagnosis, treatment, or clinical consultation. Always seek the advice of your ophthalmologist or other qualified healthcare provider regarding any ocular condition, changes in visual health, or before starting or modifying any prescribed medication.